In a report released today, Serge Belanger from Needham maintained a Buy rating on Evolus (EOLS – Research Report), with a price target of $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Serge Belanger has given his Buy rating due to a combination of factors including the promising launch of Evolysse fillers and the strong commercial performance of Jeuveau. The discussions at the conference highlighted the company’s strategic positioning in the aesthetics market, which is showing positive trends.
Additionally, the management team, represented by CFO Sandra Beaver and CMO Rui Avelar, provided insights into how Evolus is navigating potential challenges such as tariffs, which further supports confidence in the company’s growth prospects. These elements collectively contribute to the optimistic outlook for Evolus’s stock.
Belanger covers the Healthcare sector, focusing on stocks such as Evolus, Arcutis Biotherapeutics, and Cytokinetics. According to TipRanks, Belanger has an average return of -3.3% and a 34.33% success rate on recommended stocks.